

**2026 Vascular Annual Meeting  
Late Breaking Abstracts  
Submission Polices and Guidelines**

**Late Breaking Abstracts** are innovative and provide the latest breakthroughs in clinical science. The sessions provide exposure and recognition for studies likely to have a significant impact on clinical practice and/or to make significant advances in a scientific field. They must highlight important results obtained **after the January 7th** abstract submission deadline. **We will not be accepting duplicate abstract submissions from the call for abstracts that took place November 2025-January 2026.**

**In-person Presentation of Any Accepted Abstract is Required**

All presenting authors should be at the meeting, in-person, to present their work. Use of Zoom or any other streaming platform will **not** be available for a virtual lecture.

**Maintenance of Certification (MOC) Self-Assessment Questions are Required**

All submitting authors will need to provide one (1) self-assessment question at the time of abstract submission. (This does not apply to video submissions.) Guidelines on how to write a proper question will be made available via the submission portal, online at *vascular.org* and through various SVS communication channels.

**Statement Regarding Identifying Information**

To ensure a fair and unbiased review process, please refrain from including any identifying information in your submission. This includes, but is not limited to:

- Author names, affiliations, or contact information.
- Acknowledgments that reference specific individuals, institutions, or grants.
- References to your previous work that could reveal your identity (use "Author" or "this work" in place of self-citations).

Submissions that include identifying information may be returned for revisions or disqualified from the review process.

**Use of Proprietary Drug Names**

Do not use proprietary drug names in your abstract body or title; use generic names instead (e.g., "Herceptin" should be written as "trastuzumab"). If the proprietary name is the only one used for the particular drug or product to which you are referring (e.g., HercepTest or CyberKnife), you may use that name; however, do not include a trademark or registration symbol.

**Redundant Publication/Presentation Withdrawal**

The work represented in the abstract must NOT have been presented nor published at any scientific meeting or journal prior to that year's Vascular Annual Meeting. Failure to comply with the above rules will result in the abstract being rejected or later withdrawn. In addition, the penalty may include a one-year ban from presentation at the Vascular Annual Meeting, subject to the discretion of the Program Committee.

It is the responsibility of the submitting author or sponsoring SVS member to consult with the Program Committee prior to submission if there is any question regarding possible redundancy of the work to be presented. Direct inquiries to [vameducation@vascularsociety.org](mailto:vameducation@vascularsociety.org).

=====

## ABSTRACTS

- The Objectives/Methods/Results/Conclusions sections are limited to 400 words **total**.
- Authors are not restricted by the number of abstracts and/or videos submitted. However, no more than **15** authors per submission are allowed. Ensure **ALL** authors are included at the time of submission. **You will not be able to add an author after the portal closes or acceptance.**
- **Author Disclosures will no longer be collected at this stage in order to streamline the submission process.**
- Abstract submissions must be entered in the English language.
- Updates and edits to submissions can be made as needed prior to the submission deadline.
- Titles and abstract content may not include author, institutional and/or proprietary names.
- You **must** identify the following roles during the submission process:
  - Submitting Author - the author who enters the abstract information into the online system. All administrative correspondence regarding the submission will be sent to this individual.
  - Presenting Author - the author who will present the submission on-site during the session.
  - Submitting and Presenting Author - the author who will both enter the abstract information into the online system and present the material on-site during the session.
  - Co-Author - an individual who has contributed data or other information to the submission.
  - Senior Author - the author who is primarily responsible for the research
  - Senior Author Discussant - if the author presenting the paper is a medical student or trainee, a Senior Author Discussant will be identified and present at the podium during the presentation to answer questions on the abstract.

### Author

It is SVS policy that either the submitting author or one of the co-authors of each abstract be an SVS member. If neither the submitting author nor the co-authors are members, then a member must sponsor the abstract. SVS sends all correspondence to the submitting author or member sponsor regarding the submission. Papers may be presented by a student, resident or fellow; however, the senior author must be present in the audience during the discussion phase of the paper. The presenting author must have a command of the English language and be able to respond to questions in understandable English.

### ACCME Standards

The Education Council and Committees oversee the development and implementation of CME activities and as such volunteers must adhere to The Standards for Integrity and Independence in Accredited Continuing Education. Per these requirements, owners, executives and employees of ineligible companies (formerly known as commercial interest) are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty. These individuals cannot influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education, except in the limited circumstances outlined in Standard 3.2. All volunteers involved as planners or faculty will be required to disclose all financial relationships within the prior 24 months.

### Graphics

- Tables must be:
  - Editable, and submitted as a Word document.
  - Numbered with Roman numerals and have a title.
  - Cited in the text of the abstract in the following format: (Table I).
- Figures must be:
  - Sharp, and all text is to be legible (when the image is sized to 3" wide).
  - Numbered, and accompanied by an editable legend.
  - Cited in the text of the abstract in the following format: (Fig 1).
  - JPG is the only accepted format for figures. Maximum file size is 15 MB.
- Miscellaneous
  - No more than **two** images may be uploaded. **MULTIPLE PANEL FIGURES ARE NOT ALLOWED**

(i.e., a single figure with parts 1A, 1B, 1C).

- Images must be the original, unpublished property of the author(s). Written permission must be obtained from the rights-holder to reuse any copyrighted material. Resolution should be 300 DPI at 3" wide or larger.

### **AI Policy**

Where authors use generative artificial intelligence (AI) and AI-assisted technologies in the writing process, authors should only use these technologies to improve readability and language. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans, as outlined in Elsevier's [AI policy for authors](#).

#### Disclosure instructions

Authors must disclose the use of generative AI and AI-assisted technologies in the writing process by adding a statement at the end of their manuscript in the core manuscript file, before the References list. The statement should be placed in a new section entitled 'Declaration of Generative AI and AI-assisted technologies in the writing process'.

Statement: During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON].

After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

This declaration does not apply to the use of basic tools for checking grammar, spelling, references, etc. If there is nothing to disclose, there is no need to add a statement.

More information can be found at the SVS website: <https://vascular.org/vascular-specialists/research/journals/declaration-generative-ai-scientific-writing>